Summary
Company Research, the leading business intelligence provider, has released its latest report, “Pharmaceutical Partnership Deal Terminations” which provides key data, information and analysis of the major deals terminated in pharma industry in the period January, 2010, to June, 2011. The report provides a comprehensive insight into the partner companies involved in the deal, the licensed product and its clinical trial data, terms and conditions of the deal and deal value, and reason for deal termination. The report discusses the most common reasons for the termination of deals in the pharma industry. The report also provides an analysis of the therapeutic areas and the range of deal values of the terminated deals.
The most common reason for the termination of partnership deals was a change in company strategy, often due to a company’s merger or acquisition activities, or due to a revision of its existing product pipeline. Other causes for the termination of deals included negative results in clinical trials designed to evaluate the safety and efficacy of the drug, delay in drug development, caused by rejection of a Marketing Authorization Application (MAA) or New Drug Application (NDA) by the regulatory authorities, increasing development costs of drug candidates, and disagreement between the licensor and licensee. The majority of terminated deals were in the therapeutic areas of CNS and infectious diseases. Also, most of the terminated deals had a deal value between $400m and $600m.
This report is built using data and information sourced from proprietary databases and secondary research and in-house analysis by Company Research’s team of industry experts.
Scope
- The report analyzes the major deals terminated in the pharma industry in the period January, 2010, to June 2011, along with the licensed products, major reasons for deal terminations and therapeutic areas and the deal values of terminated deals.
- Comparative analysis of the causes, therapeutic areas and deal values of major terminated deals in the period January 2010, to June 2011
- Detailed description of the top 20 terminated licensing deals by deal value in the period January 2010, to June 2011
- For each deal, this description includes analysis of partner companies, licensed product description, a deal overview with terms and conditions, deal value and the reason for deal termination
- Geographies: Global
For more information, please visit:
http://www.aarkstore.com/reports/Pharmaceutical-Partnership-Deal-Terminations-155028.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
Company Research, the leading business intelligence provider, has released its latest report, “Pharmaceutical Partnership Deal Terminations” which provides key data, information and analysis of the major deals terminated in pharma industry in the period January, 2010, to June, 2011. The report provides a comprehensive insight into the partner companies involved in the deal, the licensed product and its clinical trial data, terms and conditions of the deal and deal value, and reason for deal termination. The report discusses the most common reasons for the termination of deals in the pharma industry. The report also provides an analysis of the therapeutic areas and the range of deal values of the terminated deals.
The most common reason for the termination of partnership deals was a change in company strategy, often due to a company’s merger or acquisition activities, or due to a revision of its existing product pipeline. Other causes for the termination of deals included negative results in clinical trials designed to evaluate the safety and efficacy of the drug, delay in drug development, caused by rejection of a Marketing Authorization Application (MAA) or New Drug Application (NDA) by the regulatory authorities, increasing development costs of drug candidates, and disagreement between the licensor and licensee. The majority of terminated deals were in the therapeutic areas of CNS and infectious diseases. Also, most of the terminated deals had a deal value between $400m and $600m.
This report is built using data and information sourced from proprietary databases and secondary research and in-house analysis by Company Research’s team of industry experts.
Scope
- The report analyzes the major deals terminated in the pharma industry in the period January, 2010, to June 2011, along with the licensed products, major reasons for deal terminations and therapeutic areas and the deal values of terminated deals.
- Comparative analysis of the causes, therapeutic areas and deal values of major terminated deals in the period January 2010, to June 2011
- Detailed description of the top 20 terminated licensing deals by deal value in the period January 2010, to June 2011
- For each deal, this description includes analysis of partner companies, licensed product description, a deal overview with terms and conditions, deal value and the reason for deal termination
- Geographies: Global
For more information, please visit:
http://www.aarkstore.com/reports/Pharmaceutical-Partnership-Deal-Terminations-155028.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
No comments:
Post a Comment